Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study.

"Conflict-of-interest disclosure: G.M. received meeting attendance grants from 10.13039/100002429Amgen, 10.13039/501100016387Grifols, and 10.13039/100004336Novartis; is a coordinator of research studies granted by 10.13039/100002429Amgen, CSL Behring, 10.13039/501100016387Grifols, 10.13039/100004336Novartis, and 10.13039/100004339Sanofi; has participated in educational sessions funded by 10.13039/100002429Amgen, 10.13039/501100016387Grifols, and 10.13039/100004336Novartis; and is on the boards of Amgen, Argenx, Grifols, Novartis, Sanofi, and Sobi. M.M. participated in educational sessions and boards of Amgen, Argenx, Novartis, Sobi, and UCB. The remaining authors declare no competing financial interests."

"This study was academic, funded by the Société Nationale Française de Médecine Interne and the University Hospital of Toulouse."